COVID-19: Bharat Parenterals gets DCGI nod for favipiravir oral suspension

COVID-19: Bharat Parenterals gets DCGI nod for favipiravir oral suspension

PTIUpdated: Sunday, May 23, 2021, 06:39 PM IST
article-image
File/ COVID-19 patients undergo treatment at Guru Tegh Bahadur COVID care centre at Gurdwara Rakab Ganj Sahib in New Delhi, Thursday, May, 20, 2021. | (PTI Photo)

Drug firm Bharat Parenterals on Saturday said it has received approval from the Drugs Controller General of India (DCGI) for favipiravir oral suspension, to be used for treatment of COVID-19 patients.

The company has received licence and authorisation from DCGI to manufacture and market favipiravir oral suspension l00mg/ml, Bharat Parenterals said in a regulatory filing.

Favipiravir, an antiviral drug, was approved in Japan in 2014 for the treatment of novel or re-emerging influenza virus infections.

(To receive our E-paper on WhatsApp daily, please click here.  To receive it on Telegram, please click here. We permit sharing of the paper's PDF on WhatsApp and other social media platforms.)

RECENT STORIES

NBCC, HSCC receive orders worth Rs 487.41 cr

NBCC, HSCC receive orders worth Rs 487.41 cr

Mondelez to invest Rs 4,000 cr in India in next 3 years: Report

Mondelez to invest Rs 4,000 cr in India in next 3 years: Report

Income tax return filing: How to file ITR-1 Sahaj and the documents required

Income tax return filing: How to file  ITR-1 Sahaj and the documents required

REC subsidiaries transfer 6 projects to Power Grid Corporation

REC subsidiaries transfer 6 projects to Power Grid Corporation

UltraTech Cement announces allotment of 2,000 equity shares

UltraTech Cement announces allotment of 2,000 equity shares